PDCD1 and neoplasm: Immune checkpoint inhibitors with targets like programmed cell death protein 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have been the mainstay of successful tumor immunotherapy treatments until recently [7].